Continuation of Inflectra for Juvenile Idiopathic Arthritis

Medical Necessity Assessment

The patient has demonstrated a positive clinical response to infliximab therapy as evidenced by a clinical disease activity score of zero, resolved pain, and stable examination findings 1
The patient is appropriately receiving infliximab in combination with methotrexate, which is the recommended approach to improve efficacy and reduce immunogenicity 2
Maintenance therapy is preferred over interrupted therapy to avoid the risk of developing antibodies to infliximab and subsequent loss of efficacy 2

The patient has demonstrated stable drug levels without antibodies, which supports continuing the current regimen 1
The patient's inflammatory markers have normalized, further supporting the efficacy of the current treatment 1
The patient has a specific subtype with sacroiliitis, which is an appropriate indication for TNF inhibitor therapy 3

Continue regular laboratory monitoring with infusions to assess for potential adverse effects 3
Maintain vigilance for signs of breakthrough arthritis, with a low threshold for repeat imaging if there are persistent concerns 1
Consider dose adjustment if imaging shows evidence of inflammation despite clinical stability 1
Monitor for potential adverse events including infusion reactions, which occur in up to 20% of patients 2
Monitor for potential adverse events including serious infections, particularly tuberculosis 2

Interrupted therapy should be avoided as it increases the risk of developing antibodies to infliximab and subsequent loss of efficacy 2
If breakthrough symptoms occur, checking drug levels and antibodies would be appropriate before considering dose escalation or switching therapy 1
The patient's recent symptoms resolved with medication and were likely related to increased physical activity rather than disease flare, but continued monitoring is warranted 1

Regular assessment of disease activity should continue to ensure ongoing benefit 1